Contribution of bone and mineral abnormalities to cardiovascular disease in patients with chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 3, Issue 3, 2008, Pages 836-843

  Raggi, Paolo ^a   Kleerekoper, Michael ^b,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST JOSEPH MERCY HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DEMINERALIZATION; BONE REMODELING; CALCINOSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; HUMAN; METABOLIC BONE DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

BONE DEMINERALIZATION, PATHOLOGIC; BONE DISEASES, METABOLIC; BONE REMODELING; CALCINOSIS; CARDIOVASCULAR DISEASES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; RISK FACTORS; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

EID: 44649103426     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02910707     Document Type: Short Survey

References (118)

1. Arias E, Anderson RN, Kung HC, Murphy SL, Kochanek KD: Deaths: Final data for 2001. Natl Vital Stat Rep 52: 1-115, 2003
2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1-12, 2003
3. State-specific trends in chronic kidney failure - United States, 1990-2001. MMWR Morb Mortal Wkly Rep 53: 918-920, 2004
4. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1-S266, 2002
5. Giannini S, D'Angelo A, Carraro G, Antonello A, Di Landro D, Marchini F, Plebani M, Zaninotto M, Rigotti P, Sartori L, Crepaldi G: Persistently increased bone turnover and low bone density in long-term survivors to kidney transplantation. Clin Nephrol 56: 353-363, 2001
6. Jones CA, McQuillan GM, Kusek JW, Eberhardt MS, Herman WH, Coresh J, Salive M, Jones CP, Agodoa LY: Serum creatinine levels in the US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 32: 992-999, 1998
7. Young EW: An improved understanding of the causes of end-stage renal disease. Semin Nephrol 17: 170-175, 1997
8. Slatopolsky E, Brown A, Dusso A: Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl 73: S14-S19, 1999
9. Elder G: Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res 17: 2094-2105, 2002
10. Elder GJ, Mackun K: 25-Hydroxyvitamin D deficiency and diabetes predict reduced BMD in patients with chronic kidney disease. J Bone Miner Res 21: 1778-1784, 2006
11. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
12. Alem AM, Sherrard DJ, Gillen DL, Weiss NS, Beresford SA, Heckbert SR, Wong C, Stehman-Breen C: Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58: 396-399, 2000
13. Meier C, Nguyen TV, Center JR, Seibel MJ, Eisman JA: Bone resorption and osteoporotic fractures in elderly men: The Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 20: 579-587, 2005
14. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A, Vanholder R, Walker R, Wang H: The burden of kidney disease: Improving global outcomes. Kidney Int 66: 1310-1314, 2004
15. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G: Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69: 1945-1953, 2006
16. Rickers, H, Christiansen C, Christensen P, Christensen M, Rodbro P: Serum concentrations of vitamin D metabolites in different degrees of impaired renal function: Estimation of renal and extrarenal secretion rate of 24,25-dihydroxyvitamin D. Nephron 39: 267-271, 1985
17. Holick MF: Vitamin D deficiency. N Engl J Med 357: 266-281, 2007
18. Hendy GN, Hruska KA, Mathew S, Goltzman D: New insights into mineral and skeletal regulation by active forms of vitamin D. Kidney Int 69: 218-223, 2006
19. Rodriguez M, Canadillas S, Lopez I, Aguilera-Tejero E, Almaden Y: Regulation of parathyroid function in chronic renal failure. J Bone Miner Metab 24: 164-168, 2006
20. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 71: 31-38, 2007
21. Kates DM, Sherrard DJ, Andress DL: Evidence that serum phosphate is independently associated with serum PTH in patients with chronic renal failure. Am J Kidney Dis 30: 809-813, 1997
22. Fukagawa M, Nakanishi S, Fujii H, Hamada Y, Abe T: Regulation of parathyroid function in chronic kidney disease (CKD). Clin Exp Nephrol 10: 175-179, 2006
23. Reichel H, Deibert B, Schmidt-Gayk H, Ritz E: Calcium metabolism in early chronic renal failure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 6: 162-169, 1991
24. Brown AJ: Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38: S3-S19, 2001
25. Panda DK, Miao D, Bolivar I, Li J, Huo R, Hendy GN, Goltzman D: Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 279: 16754-16766, 2004
26. Hruska KA, Saab G, Mathew S, Lund R: Renal osteodystrophy, phosphate homeostasis, and vascular calcification. Semin Dial 20: 309-315, 2007
27. Coen G: Adynamic bone disease: An update and overview. J Nephrol 18: 117-122, 2005
28. Hamdy NA: The spectrum of renal bone disease. Nephrol Dial Transplant 10[Suppl 4]: 14-18, discussion 37-43, 1995
29. Buargub MA, Nabulsi MF, Shafeh TA: Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: A cross sectional study of 103 patients. Saudi J Kidney Dis Transpl 17: 401-407, 2006
30. Salusky IB, Goodman WG: Adynamic renal osteodystrophy: Is there a problem? J Am Soc Nephrol 12: 1978-1985, 2001
31. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K: Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56: 1084-1093, 1999
32. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70: 1358-1366, 2006
33. Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver JM, Smogorzewski MT, Slatopolsky EM, McCann L: Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis 43: 558-565, 2004
34. Coco M, Rush H: Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36: 1115-1121, 2000
35. Raggi P, James G, Burke SK, Bommer J, Chasan-Taber S, Holzer H, Braun J, Chertow GM: Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis. J Bone Miner Res 20: 764-772, 2005
36. Kurz P, Tsobanelis T, Roth P, Werner E, Ewald U, Grutzmacher P, Schoeppe W, Vlachojannis J: Differences in calcium kinetic pattern between CAPD and HD patients. Clin Nephrol 44: 255-261, 1995
37. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC: Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15: 1943-1951, 2004
38. Kestenbaum B, Andress DL, Schwartz SM, Gillen DL, Seliger SL, Jadav PR, Sherrard DJ, Stehman-Breen C: Survival following parathyroidectomy among United States dialysis patients. Kidney Int 66: 2010-2016, 2004
39. Avram MM, Mittman N, Myint MM, Fein P: Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 38: 1351-1357, 2001
40. Collins AJ, Li S, Gilbertson DT, Liu J, Chen SC, Herzog CA: Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int Suppl S24-S31, 2003
41. Sarnak MJ, Levey AS: Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 35: S117-S131, 2000
42. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, Klag MJ: Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: The CHOICE Study. J Am Soc Nephrol 13: 1918-1927, 2002
43. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ: Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 228: 826-833, 2003
44. Arad Y, Goodman KJ, Roth M, Newstein D, Guerci AD: Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: The St. Francis Heart Study. J Am Coll Cardiol 46: 158-165, 2005
45. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC: Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 291: 210-215, 2004
46. Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM: Influence of biochemical alterations on arterial stiffness in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 18: 535-541, 1998
47. Guerin AP, London GM, Marchais SJ, Metivier F: Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021, 2000
48. Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM: Cardiac calcification in adult hemodialysis patients: A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39: 695-701, 2002
49. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223, 2000
50. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM: Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441, 2007
51. Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, Takishita S: Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol 8: 54-58, 2004
52. Raggi P, Bellasi A, Ferramosca E, Islam T, Muntner P, Block GA: Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int 71: 802-807, 2007
53. Watanabe H, Ohtsuka S, Kakihana M, Sugishita Y: Coronary circulation in dogs with an experimental decrease in aortic compliance. J Am Coll Cardiol 21: 1497-1506, 1993
54. Weiner DE, Tighiouart H, Vlagopoulos PT, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16: 1803-1810, 2005
55. Kingwell BA, Ahimastos AA: Arterial stiffness and coronary ischemic disease. Adv Cardiol 44: 125-138, 2007
56. Cheriyan J, Wilkinson IB: Role of increased aortic stiffness in the pathogenesis of heart failure. Curr Heart Fail Rep 4: 121-126, 2007
57. Saleh FN, Schirmer H, Sundsfjord J, Jorde R: Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 24: 2054-2060, 2003
58. Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, Sanderson JE: Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: A prospective study. J Am Soc Nephrol 14: 159-168, 2003
59. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Goncalves M, Negrao AP: A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 19: 1480-1488, 2004
60. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003
61. Rogers NM, Teubner DJ, Coates PT: Calcific uremic arteriolopathy: Advances in pathogenesis and treatment. Semin Dial 20: 150-157, 2007
62. Goldsmith D, Ritz E, Covic A: Vascular calcification: A stiff challenge for the nephrologist - Does preventing bone disease cause arterial disease? Kidney Int 66: 1315-1333, 2004
63. Duh QY, Lim RC, Clark OH: Calciphylaxis in secondary hyperparathyroidism: Diagnosis and parathyroidectomy. Arch Surg 126: 1213-1218, discussion 1218-1219, 1991
64. Girotto JA, Harmon JW, Ratner LE, Nicol TL, Wong L, Chen H: Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 130: 645-650, discussion 650-651, 2001
65. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483, 2000
66. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD: Survival predictability of time-varying indicators of bone disease in maintenance hemo-dialysis patients. Kidney Int 70: 771-780, 2006
67. Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK: Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19: 1489-1496, 2004
68. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendorogto M, Draibe SA, Moyses RM, Neves KR, Jorgetti V, Blair A, Guiberteau R, Fernandes Canziani ME: Coronary calcification in hemodialysis patients: The contribution of traditional and uremia-related risk factors. Kidney Int 67: 1576-1582, 2005
69. Reynolds JL, Joarmides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM: Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: A potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15: 2857-2867, 2004
70. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM: Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: E10-E17, 2000
71. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K: Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638-647, 2002
72. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX: Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 63: 1003-1011, 2003
73. Chen NX, O'Neill KD, Duan D, Moe SM: Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62: 1724-1731, 2002
74. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM: Smooth muscle cell phenotypic transition associated with calcification: Upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89: 1147-1154, 2001
75. El-Maadawy S, Kaartinen MT, Schinke T, Murshed M, Karsenty G, McKee MD: Cartilage formation and calcification in arteries of mice lacking matrix Gla protein. Connect Tissue Res 44[Suppl 1]: 272-278, 2003
76. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G: Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386: 78-81, 1997
77. Giachelli CM, Bae N, Almeida. M, Denhardt DT, Alpers CE, Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92: 1686-1696, 1993
78. Bostrom K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL: Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest 91: 1800-1809, 1993
79. Chen NX, Duan D, O'Neill KD, Wolisi GO, Koczman JJ, Laclair R, Moe SM: The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int 70: 1046-1053, 2006
80. Shanahan CM, Cary NR, Metcalfe JC, Weissberg PL: High expression of genes for calcification-regulating proteins in human atherosclerotic plaques. J Clin Invest 93: 2393-2402, 1994
81. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS: Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268, 1998
82. Kataoka H, Sharma K: Renal handling of adipokines. Contrib Nephrol 151: 91-105, 2006
83. Ciccone M, Vettor R, Pannacciulli N, Minenna A, Bellacicco M, Rizzon P, Giorgino R, De Pergola G: Plasma leptin is independently associated with the intima-media thickness of the common carotid artery. Int J Obes Relat Metab Disord 25: 805-810, 2001
84. Iribarren C, Husson G, Go AS, Lo JC, Fair JM, Rubin GD, Hlatky MA, Fortmann SP: Plasma leptin levels and coronary artery calcification in older adults. J Clin Endocrinol Metab 92: 729-732, 2007
85. Reilly MP, Iqbal N, Schutta M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE: Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 89: 3872-3878, 2004
86. van der Vleuten GM, Veerkamp MJ, van Tits LJ, Toenhake H, den Heijer M, Stalenhoef AF, de Graaf J: Elevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVD. Atherosclerosis 183: 355-360, 2005
87. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N: Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 104: 3052-3056, 2001
88. Kang SM, Kwon HM, Hong BK, Kim D, Kim IJ, Choi EY, Jang Y, Kim HS, Kim MS, Kwon HC: Expression of leptin receptor (Ob-R) in human atherosclerotic lesions: Potential role in intimal neovascularization. Yonsei Med J 41: 68-75, 2000
89. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL: Leptin enhances the calcification of vascular cells: Artery wall as a target of leptin. Circ Res 88: 954-960, 2001
90. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW: Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham Heart Study. Calcif Tissue Int 68: 271-276, 2001
91. Samelson EJ, Kiel DP, Broe KE, Zhang Y, Cupples LA, Hannan MT, Wilson PW, Levy D, Williams SA, Vaccarino V: Metacarpal cortical area and risk of coronary heart disease: The Framingham Study. Am J Epidemiol 159: 589-595, 2004
92. Hak AE, Pols, HA, van Hemert AM, Hofman A, Witteman JC: Progression of aortic calcification is associated with metacarpal bone loss during menopause: A population-based longitudinal study. Arterioscler Thromb Vasc Biol 20: 1926-1931, 2000
93. Marcovitz PA, Tran HH, Franklin BA, O'Neill WW, Yerkey M, Boura J, Kleerekoper M, Dickinson CZ: Usefulness of bone mineral density to predict significant coronary artery disease. Am J Cardiol 96: 1059-1063, 2005
94. van der Klift M, Pols HA, Hak AE, Witteman JC, Hofman A, de Laet CE: Bone mineral density and the risk of peripheral arterial disease: The Rotterdam Study. Calcif Tissue Int 70: 443-449, 2002
95. Aksoy Y, Yagmur C, Tekin GO, Yagmur J, Topal E, Kekilli E, Turhan H, Kosar F, Yetkin E: Aortic valve calcification: Association with bone mineral density and cardiovascular risk factors. Coron Artery Dis 16: 379-383, 2005
96. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V: Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89: 4246-4253, 2004
97. Taal MW, Roe S, Masud T, Green D, Porter C, Cassidy MJ: Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 63: 1116-1120, 2003
98. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC: Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 27: 394-401, 1996
99. Fujimoto N, Iseki K, Tokuyama K, Tamashiro M, Takishita S: Significance of coronary artery calcification score (CACS) for the detection of coronary artery disease (CAD) in chronic dialysis patients. Clin Chim Acta 367: 98-102, 2006
100. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P: Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension 49: 1278-1284, 2007
101. Parkinson IS, Ward MK, Feest TG, Fawcett RW, Kerr DN: Fracturing dialysis osteodystrophy and dialysis encephalopathy: An epidemiological survey. Lancet 1: 406-409, 1979
102. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P: Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 68: 1815-1824, 2005
103. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
104. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42: S1-201, 2003
105. Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM: Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: A randomized clinical trial. Arthritis Rheum 52: 290-295, 2005
106. Chertow GM, Burke SK, Dillon MA, Slatopolsky E: Longterm effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14: 2907-2914, 1999
107. Ferramosca E, Burke S, Chasan-Taber S, Ratti C, Chertow GM, Raggi P: Potential antiatherogenic and anti-inflammatory properties of sevelamer in maintenance hemodialysis patients. Am Heart J 149: 820-825, 2005
108. Raggi P, Bommer J, Chertow GM: Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 13: 134 -141, 2004
109. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130-1137, 2007
110. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46: 1160-1166, 1994
111. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R: Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 16: 1115-1125, 2005
112. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003
113. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70: 1858-1865, 2006
114. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF: Meta-analysis: Vitamin D compounds in chronic kidney disease. Ann Intern Med 147: 840-853, 2007
115. Ruedin P, Rizzoli R, Slosman D, Leski M, Bonjour JP: Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure. Kidney Int 45: 245-252, 1994
116. Rix M, Eskildsen P, Olgaard K: Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 19: 870-876, 2004
117. Hudson JQ: Secondary hyperparathyroidism in chronic kidney disease: Focus on clinical consequences and vitamin D therapies. Ann Pharmacother 40: 1594-1593, 2006
118. Drueke TB: Calcimimetics versus vitamin D: What are their relative roles? Blood Purif 22: 38-43, 2004